Invention Publication
- Patent Title: CO-TREATMENT WITH CDK4/6 AND CDK2 INHIBITORS TO SUPPRESS TUMOR ADAPTATION TO CDK2 INHIBITORS
-
Application No.: US17995619Application Date: 2021-04-07
-
Publication No.: US20230158034A1Publication Date: 2023-05-25
- Inventor: Mansi Arora , Stephen George Dann , Nichol Lee Goodman Miller , Sabrina Spencer , Todd Lee VanArsdale
- Applicant: Pfizer Inc. , THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.,The Regents of the University of Colorado, a body corporate
- Current Assignee: Pfizer Inc.,The Regents of the University of Colorado, a body corporate
- Current Assignee Address: US NY New York; US CO Denver
- International Application: PCT/IB2021/052894 2021.04.07
- Date entered country: 2022-10-06
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/506 ; A61P35/00
Abstract:
The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.
Information query
IPC分类:
